[go: up one dir, main page]

AR109650A1 - Compuestos de heteroarilcarboxamida como inhibidores de ripk2 - Google Patents

Compuestos de heteroarilcarboxamida como inhibidores de ripk2

Info

Publication number
AR109650A1
AR109650A1 ARP170102539A ARP170102539A AR109650A1 AR 109650 A1 AR109650 A1 AR 109650A1 AR P170102539 A ARP170102539 A AR P170102539A AR P170102539 A ARP170102539 A AR P170102539A AR 109650 A1 AR109650 A1 AR 109650A1
Authority
AR
Argentina
Prior art keywords
3alkyl
6alkyl
optionally substituted
membered
compounds
Prior art date
Application number
ARP170102539A
Other languages
English (en)
Inventor
Zhonghua Zhang
Maolin Yu
Craig Andrew Miller
Pingrong Liu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR109650A1 publication Critical patent/AR109650A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

También composiciones farmacéuticas que comprenden estos compuestos, métodos para usar estos compuestos en el tratamiento de varias enfermedades y trastornos, procesos para preparar estos compuestos e intermediarios útiles en estos procesos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o sales de aquel aceptables desde el punto de vista farmacéutico, en donde X es N e Y es CH; o X es CH e Y es N; HET es un anillo de heteroarilo de 5 miembros que contiene de 1 a 3 heteroátomos seleccionados de nitrógeno y azufre, en donde cada anillo de heteroarilo se sustituye opcionalmente con 1 a 2 grupos de sustituyentes seleccionados independientemente de R³ y R⁴; o HET es un anillo de heteroarilo de 5 miembros que contiene de 1 a 3 heteroátomos seleccionados de nitrógeno y azufre, en donde cada anillo de heteroarilo se sustituye con 2 grupos de sustituyentes seleccionados de Rᵃ y Rᵇ, en donde Rᵃ y Rᵇ, junto con los átomos a los que están unidos, forman un anillo heterocíclico o de heteroarilo de 5 - 6 miembros que puede ser opcionalmente sustituido con 1 a 2 sustituyentes seleccionados de R³ y R⁴; R¹ es hidrógeno o F; R² es C₁₋₃alquilo o Cl; R³ y R⁴ se seleccionan cada uno independientemente de: (a) -H, (b) -OR⁵, (c) -O-C₁₋₆alquil-O-C₁₋₃alquilo (d) -O-C₃₋₆cicloalquilo, (e) -C(O)R⁵, (f) C₁₋₆alquilo opcionalmente sustituido con 1 a 3 -OH, flúor, heterociclilo opcionalmente sustituido con oxo, C₃₋₆cicloalquilo, -CO₂R⁵, -O-C₁₋₆alquilo, arilo, -N(R⁵)(R⁶) o -C(O)N(R⁵)(R⁶), (g) C₃₋₆cicloalquilo opcionalmente sustituido con 1 a 3 -OH, 1 a 3 flúor, C₁₋₆alquilo, -OC₁₋₆alquilo, C₁₋₆alquil-OC₁₋₆alquilo, C₁₋₆alquilo-OH, CF₃, -OC₃₋₆cicloalquilo, -CO₂H, -CO₂R⁵, C₃₋₆cicloalquilo, heteroarilo de 5 - 6 miembros, C₃₋₆heterociclilo, N(R⁵)(R⁶) o -C(O)N(R⁵)(R⁶), (h) -CO₂R⁵, (i) -C(O)N(R⁵)(R⁶), (j) -S(O)₂N(R⁵)(R⁶), (k) -S(O)ₙ-R⁵, (l) un grupo heteroarilo de 5 - 6 miembros opcionalmente sustituido con 1 a 3 grupos seleccionados de C₁₋₆alquilo, C₃₋₆cicloalquilo, halógeno, -CF₃, -OH, -(CH₂)ₙCO₂R⁵, -C(O)N(R⁵)(R⁶), -N(R⁵)(R⁶), -NH-SO₂C₁₋₆alquilo, C₁₋₆alcoxilo, C₁₋₆alquil-O-C₁₋₃alquilo, C₁₋₆alquilhidroxilo, C₁₋₃alquil-CN, oxo, fenilo opcionalmente sustituido con halógeno y -S(O)ₙC₁₋₆alquilo, (m) grupo heterociclilo monocíclico, bicíclico o espirocíclico de 4 - 10 miembros que contiene N, S u O, en donde cada heterociclo es opcionalmente sustituido con 1 - 3 sustituyentes seleccionados de anillo heterocíclico de 3 - 6 miembros, halógeno, -C₁₋₃alquilo, -C₁₋₃alquil-O-C₁₋₃alquilo y -C₁₋₃alquil-C(O)N(R⁵)(R⁶), (n) arilo, (o) -N(R⁵)(R⁶); R⁵ y R⁶ se seleccionan cada uno independientemente de -H, heterociclilo de 4 - 6 miembros, -C(O)-C₁₋₃alquil-C(O)-C₁₋₃cicloalquilo y -C₁₋₆alquilo, en donde cada R⁵ y R⁶ se sustituye independientemente, de manera opcional, con -OH, C₃₋₆cicloalquilo, -C₁₋₃alquilo, -O-C₁₋₃alquilo, -NH-C₁₋₃alquilo o -N-(C₁₋₃alquilo)₂; o R⁵ y R⁶, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico de 4 - 6 miembros opcionalmente sustituido con metilo; y n es 0, 1 ó 2.
ARP170102539A 2016-09-15 2017-09-14 Compuestos de heteroarilcarboxamida como inhibidores de ripk2 AR109650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394779P 2016-09-15 2016-09-15

Publications (1)

Publication Number Publication Date
AR109650A1 true AR109650A1 (es) 2019-01-09

Family

ID=59901598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102539A AR109650A1 (es) 2016-09-15 2017-09-14 Compuestos de heteroarilcarboxamida como inhibidores de ripk2

Country Status (31)

Country Link
US (4) US10138241B2 (es)
EP (1) EP3512833B1 (es)
JP (1) JP6733050B2 (es)
KR (1) KR102472736B1 (es)
CN (1) CN110023290B (es)
AR (1) AR109650A1 (es)
AU (1) AU2017327539B2 (es)
BR (1) BR112019003320B1 (es)
CL (1) CL2019000476A1 (es)
CO (1) CO2019001181A2 (es)
CY (1) CY1123494T1 (es)
DK (1) DK3512833T3 (es)
EA (1) EA038128B1 (es)
ES (1) ES2816003T3 (es)
HR (1) HRP20201494T1 (es)
HU (1) HUE051551T2 (es)
IL (1) IL265062B (es)
LT (1) LT3512833T (es)
MA (1) MA46229B1 (es)
MX (1) MX387443B (es)
NZ (1) NZ750416A (es)
PE (1) PE20190979A1 (es)
PH (1) PH12019500497A1 (es)
PL (1) PL3512833T3 (es)
PT (1) PT3512833T (es)
RS (1) RS60729B1 (es)
SA (1) SA519401322B1 (es)
SI (1) SI3512833T1 (es)
TW (1) TWI749062B (es)
UA (1) UA123287C2 (es)
WO (1) WO2018052772A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3464336T3 (da) 2016-06-01 2022-05-09 Athira Pharma Inc Forbindelser
CN110023290B (zh) 2016-09-15 2022-08-12 勃林格殷格翰国际有限公司 作为ripk2抑制剂的杂芳基甲酰胺化合物
US10138222B2 (en) 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7458406B2 (ja) * 2018-12-21 2024-03-29 セルジーン コーポレーション Ｒｉｐｋ２のチエノピリジン阻害剤
AR118471A1 (es) * 2019-03-22 2021-10-06 Takeda Pharmaceuticals Co Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
CN119698416A (zh) 2022-06-10 2025-03-25 英特莱治疗公司 作为ripk2抑制剂的咪唑并(1,2-a)吡啶衍生物
AU2024286701A1 (en) 2023-06-09 2026-01-08 Interline Therapeutics, Inc. Methods of treating inflammatory diseases
WO2024259328A1 (en) * 2023-06-16 2024-12-19 Odyssey Therapeutics, Inc. Inhibitors of ripk2 and uses thereof
WO2025085928A1 (en) 2023-10-20 2025-04-24 Odyssey Therapeutics, Inc. Methods of treating a patient with an inflammatory bowel disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1379525T1 (sl) 2001-02-21 2007-12-31 Astrazeneca Ab Heteropoliciklične spojine in njihova uporaba kot antagonisti metabotropnih glutamatnih receptorjev
ATE482200T1 (de) 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
NZ574621A (en) 2006-07-07 2012-03-30 Boehringer Ingelheim Int Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents
CN101528717B (zh) 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
EP2245025A1 (en) 2008-02-27 2010-11-03 Merck Patent GmbH Carboxamide-heteroaryl derivatives for the treatment of diabetes
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
WO2011123609A1 (en) * 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
UY33808A (es) 2010-12-17 2012-07-31 Syngenta Participations Ag Compuestos insecticidas
CA2826059A1 (en) 2011-02-09 2012-08-16 Pierre Joseph Marcel Jung Insecticidal compounds
UY34863A (es) 2012-06-19 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Antagonistas de iap
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
US20140142129A1 (en) 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc, Methods of treating a disease or disorder associated with bruton's tyrosine kinase
PT2953942T (pt) 2013-02-06 2018-01-17 Bayer Cropscience Ag Derivados de pirazol substituídos com halogéneo como agentes pesticidas
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015101622A1 (de) 2014-01-03 2015-07-09 Bayer Cropscience Ag Neue pyrazolyl-heteroarylamide als schädlingsbekämpfungsmittel
CN107454899B (zh) 2014-10-27 2020-05-29 大学健康网络 Ripk2抑制剂及用其治疗癌症的方法
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
CN110023290B (zh) 2016-09-15 2022-08-12 勃林格殷格翰国际有限公司 作为ripk2抑制剂的杂芳基甲酰胺化合物
US10138222B2 (en) 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors

Also Published As

Publication number Publication date
JP6733050B2 (ja) 2020-07-29
LT3512833T (lt) 2020-10-12
EP3512833B1 (en) 2020-07-29
US20220081437A1 (en) 2022-03-17
KR20190047046A (ko) 2019-05-07
US20180072717A1 (en) 2018-03-15
EP3512833A1 (en) 2019-07-24
SI3512833T1 (sl) 2020-11-30
US20250042901A1 (en) 2025-02-06
RS60729B1 (sr) 2020-09-30
BR112019003320B1 (pt) 2024-02-20
US12139484B2 (en) 2024-11-12
CN110023290A (zh) 2019-07-16
MX2019003026A (es) 2019-07-01
MX387443B (es) 2025-03-18
CN110023290B (zh) 2022-08-12
DK3512833T3 (da) 2020-10-12
HRP20201494T1 (hr) 2020-12-11
TWI749062B (zh) 2021-12-11
NZ750416A (en) 2022-04-29
KR102472736B1 (ko) 2022-12-02
WO2018052772A1 (en) 2018-03-22
CA3037141A1 (en) 2018-03-22
US10138241B2 (en) 2018-11-27
TW201823227A (zh) 2018-07-01
PE20190979A1 (es) 2019-07-09
AU2017327539B2 (en) 2020-12-24
JP2019529407A (ja) 2019-10-17
PL3512833T3 (pl) 2021-01-11
PT3512833T (pt) 2020-09-24
US11130754B2 (en) 2021-09-28
CO2019001181A2 (es) 2019-02-19
SA519401322B1 (ar) 2022-05-10
UA123287C2 (uk) 2021-03-10
AU2017327539A1 (en) 2019-02-21
CL2019000476A1 (es) 2019-05-31
HUE051551T2 (hu) 2021-03-01
PH12019500497A1 (en) 2019-12-11
EA201990678A1 (ru) 2019-09-30
US20190048000A1 (en) 2019-02-14
MA46229A (fr) 2019-07-24
IL265062B (en) 2021-04-29
EA038128B1 (ru) 2021-07-09
ES2816003T3 (es) 2021-03-31
MA46229B1 (fr) 2020-10-28
CY1123494T1 (el) 2022-03-24
BR112019003320A2 (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
MX2016015544A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1.
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR104716A1 (es) Agonistas de triazol del receptor apj
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR105893A1 (es) Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR106865A1 (es) Piridinas sustituidas y métodos de uso
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR103397A1 (es) Oxoborazoles microbicidas
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal